. A summary of the viral load observed in the study of Tebas et al. 1 Patient Set-point VL (log 10 copies/ml) VL after gene therapy (log 10 copies/ml) Figure 2 , we considered the case where 5% of the normal uninfected T cells (T n ) come from the source (naive T cells) and 95% of the T n cells are formed via self-renewal (i.e. λ = 1 cells µl −1 day −1 , r = 0.057 and K = 1500 in Eq. 1). Here we study the effect of the contribution from the source on a CCR5 suicide gene therapy. We performed a parameter sensitivity analysis considering r = 0.06 and T n = 1000 (Fig. 1) for the virus free steady state, and varied λ and K solving K from K = rT n 2 /(λ + (r − δ T )T n ) (derived from Eq. 1). In panel (a) we show the effect of the relative contribution from the source for T n cells with a heterozygous CCR5 disruption (i.e. β g = 0.5β n ) considering normal gene therapy i.e. 0% contribution from the source for T g cells. In panel (b) we repeat the analysis considering a stem cell based gene therapy i.e. 5% contribution from the source for T g cells. In panels (c) and (d) we perform a similar parameter sensitivity analysis by varying the rate of infection of the unmodified T cell β n , setting other parameters the same as Fig. 2 . In panel (c) we show that for large range of β n values a suicide gene always results in a reduction of the virus load compared to the current CCR5 gene therapy (red line). In panel (d) we show that an increase in β n results in a decrease of the T n cells. Since we are simulating the chronic stage of HIV-1 infected individuals, we consider normal T cell counts of about 300 cells µl −1 . For high rates of infection (β n ≥ 5.4 × 10 −6 ), T n is less than 200 cells µl −1 which is too low for a normal chronic stage, as one expects AIDS to develop. Nevertheless, a suicide gene would always improve the normal T cell count compared to the current CCR5 gene therapy (red line).
